Post transfusionnal iron overload;Surcharges en fer et maladies hématologiques

Revue du Praticien

Volumn 56, Issue 19, 2006, Pages 2141-2145

  Rose, Christian ^a  

^a UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; ERYTHROCYTE; HEMATOPOIESIS; HUMAN; IRON OVERLOAD; PATHOPHYSIOLOGY; REVIEW;

EID: 33846061307     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Badens C, North ML, Lena-Russo D. Les bêta- thalassémies en France métropolitaine. Presse Med 2003;32:1016-21.
2. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574.
3. Rose C, Cambier N, Mahieu M, Ernst O, Fenaux P. Surcharge martiale et syndromes myélodysplasiques (SMD). Transfus Clin Biol 2001;8:422-32.
4. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
5. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
6. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
7. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf 1997;17:407-21.
8. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107:3436-41.
9. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7.
10. Penned DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44.
11. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
12. Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann N Y Acad Sci 2005;1054:175-82.
13. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
14. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62.
15. Porter J, Vichinsky E, Rose C, et al. A phase II study with ICL 670, a once daily oral iron chelator, in patients with various transfusion-dependant anamias and iron overload. Blood 2004;104:872a.